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Abstract
Background: Clinical proteomics application aims at solving a specific clinical problem within the context of a
clinical study. It has been growing rapidly in the field of biomarker discovery, especially in the area of cancer
diagnostics. Until recently, protein isoform has not been viewed as a new class of early diagnostic biomarkers for
clinical proteomics. A protein isoform is one of different forms of the same protein. Different forms of a protein may
be produced from single-nucleotide polymorphisms (SNPs), alternative splicing, or post-translational modifications
(PTMs). Previous studies have shown that protein isoforms play critical roles in tumorigenesis, disease diagnosis, and
prognosis. Identifying and characterizing protein isoforms are essential to the study of molecular mechanisms and
early detection of complex diseases such as breast cancer.
However, there are limitations with traditional methods such as EST sequencing, Microarray profiling (exon array,
Exon-exon junction array), mRNA next-generation sequencing used for protein isoform determination: 1) not in the
protein level, 2) no connectivity about connection of nonadjacent exons, 3) no SNPs and PTMs, and 4) low
reproducibility. Moreover, there exist the computational challenges of clinical proteomics studies: 1) low sensitivity
of instruments, 2) high data noise, and 3) high variability and low repeatability, although recent advances in clinical
proteomics technology, LC-MS/MS proteomics, have been used to identify candidate molecular biomarkers in
diverse range of samples, including cells, tissues, serum/plasma, and other types of body fluids.
Results: Therefore, in the paper, we presented a peptidomics method for identifying cancer-related and
isoform-specific peptide for clinical proteomics application from LC-MS/MS. First, we built a Peptidomic
Database of Human Protein Isoforms, then created a peptidomics approach to perform large-scale screen of
breast cancer-associated alternative splicing isoform markers in clinical proteomics, and lastly performed four
kinds of validations: biological validation (explainable index), exon array, statistical validation of independent
samples, and extensive pathway analysis.
Conclusions: Our results showed that alternative splicing isoform makers can act as independent markers of
breast cancer and that the method for identifying cancer-specific protein isoform biomarkers from clinical
proteomics application is an effective one for increasing the number of identified alternative splicing isoform
markers in clinical proteomics.
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Background
Clinical proteomics is the application of proteomic tech-
niques to the field of medicine with the aim of solving a
specific clinical problem within the context of a clinical
study. In the past year significant commitments from re-
search institute and development of clinical proteomics
has been witnessed. The application of clinical prote-
omic research is growing rapidly in the field of bio-
marker discovery, especially in the area of cancer
diagnostics. Clinical proteomics holds the potential of
taking a snapshot of the total protein complement of a
cell, or body fluid, and identifying proteins as potential
biomarkers for the differentiation of disease and health
[1]. The study of clinical proteomic may provide us with
opportunities in more effective strategies for early dis-
ease detection and monitoring, more effective therapies,
and developing a better understanding of disease patho-
genesis [2]. Such studies may aim at earlier or more ac-
curate diagnosis, improvement of therapeutic strategies,
and better evaluation of prognosis and/or prevention
of the disease. Although clinical proteomics currently
mainly focuses on diagnostics and biomarker discov-
ery, it includes the identification of new therapeutic
targets, drugs and vaccines for better therapeutic out-
comes and successful disease prevention. In addition,
success for a clinical proteomics requires the communication
among clinicians, statisticians/bioinformaticians and
biologists [3].
Until recently, researches have viewed protein isoform
as any of several different forms of the same protein, not
as a new class of early diagnostic biomarkers for clinical
proteomics. Protein isoforms are an essential mechanism
employed by human cells to enhance molecular func-
tional diversity encoded by the genome. For protein iso-
forms, we refer to proteins derived from allellic
polymorphisms, mRNA alternative splicing, or post-
translational modifications (PTM). Allellic polymor-
phisms in protein-coding genes commonly take the form
of single nucleotide polymorphisms (SNPs) of genes. Al-
ternative splicing occurs in 40–60 % human genes and
works by selecting specific exons and sometimes even
intronic regions of the gene into mature mRNAs. Post-
translational modifications of proteins include all chem-
ical modifications after protein translation, e.g.,
phosphorylation, glycosylation, and ubiquination. Ap-
proximately 8 % of these isoforms, including both SNPs
and alternative splicing, are generated during the process
of transcribing the coding genes into mRNA. More than
90 % of protein isoforms are created through PTMs after
the mRNA is translated into a protein.
Traditional methods have been used for protein iso-
form determination such as EST sequencing [4], Micro-
array profiling [5] (exon array [6], Exon-exon junction
array [7]), mRNA next-generation sequencing [8, 9].
However, there are several limitations with these trad-
itional methods. First, they all identify isoforms in the
transcript level, not in the protein level. Therefore, they
cannot determinate isoform quantitatively in protein
level, especially for measurement of low concentrations
in biological specimens. Second, they give no connectiv-
ity information about the connection of nonadjacent
exons. Third, they give no SNPs information about each
exon and intron. Fourth, they give no information about
posttranslational modifications of peptides. Last, the big-
gest challenge for the analysis of protein isoform with
traditional methods is their low reproducibility by other
methods such as RT-PCR. Only very few events are
identified with high confidence. Indeed, the typical out-
put is usually in the order of 10 validated alternative
splicing events, which cannot meet the requirement of
high through identification of protein isoform.
Recent advances in clinical proteomics technology, for
example, LC-MS/MS, have enabled it possible to detect
complex mixtures of proteins, peptides, carbohydrates,
DNA, drugs, and many other biologically relevant mole-
cules unique to disease processes [10] in parallel in bio-
logical samples. A modern mass spectrometry (MS)
instrument consists of three essential modules: an ion
source module that can transform molecules to be de-
tected in a sample into ionized fragments, a mass
analyzer module that can sort ions by their masses,
charges, or shapes by applying electric and magnetic
fields, and a detector module that can measure the in-
tensity or abundance of each ion fragment separated
earlier. Tandem mass spectrometry (MS/MS) has the
additional analytical modules for bombarding peptide
ions into fragment peptide ions by pipeline two MS
modules together, therefore providing peptide sequen-
cing potentials for selected peptide ions in real time. Re-
cent developments of new generations of mass
spectrometers and improvements in the field of chroma-
tography have revolutionized protein analytics. Particu-
larly the combination of liquid chromatography as a
separation tool for proteins and peptides with tandem
mass spectrometry as an identification tool referred to
as LC-MS/MS has generated a powerful and broadly
used technique in the field of proteomics [11]. LC-MS/
MS proteomics have been used to identify candidate
molecular biomarkers in diverse range of samples, in-
cluding cells, tissues, serum/plasma, and other types of
body fluids. For example, Flaubert et al. discovered highly
secreted protein biomarkers which changed significantly
in abundance corresponding with aggressiveness by using
LC-MS/MS to analyze the secreted proteomes from a
series of isogenic breast cancer cell lines varying in aggres-
siveness: non-tumorigenic MCF10A, premalignant/
tumorigenic MCF10AT, tumorigenic/locally invasive
MCF10 DCIS.com and tumorigenic/ metastatic MCF
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10CA cl. D. They obtained proteomes from conditioned
serum-free media, analyzed the tryptic peptide digests of
the secreted proteins using a Waters capillary liquid chro-
matograph coupled to the nanoflow electrospray source of
a Waters Q-TOF Ultima API-US mass spectrometer, and
separated peptide on a C18 reverse phase column [12].
Although clinical proteomics can provide better evalu-
ation of prognosis and prevention of the disease, there
exist the computational challenges of clinical proteomics
studies: 1) low sensitivity of instruments leads to many
false negatives detection of molecules, especially when
the molecules exists in low abundance and is unable to
monitor specific molecules at will that can be associated
with key phenotypes (typical in Genomics or functional
genomics assays); 2) high data noise (false positives) in-
troduced by limitation of accuracy of instruments causes
false identification of peptides or assignment to proteins
based on single peptide evidence brings uncertainty to
the value of individual peptides; and 3) high variability
and low repeatability of proteomics experiments exists
even in high-abundance proteins (variability within indi-
viduals under different physiological conditions, worse
across individuals), and the degree of variability differs
for different proteins.
Therefore, in the paper, we presented a peptidomics
method for identifying cancer-related and isoform-
specific peptide for clinical proteomics application from
LC-MS/MS which can provide hopes for improving both
the sensitivity (many abundant proteins could generate
alternative splicing isoforms in a cancer) and the specifi-
city (particular types of protein isoforms may be
uniquely regulated in a given condition) of candidate
cancer biomarkers for clinical proteomics. First, we built
a Peptidomic Database of Human Protein Isoforms, then
created a peptidomics approach to perform large-scale
screen of breast cancer-associated alternative splicing
isoform markers in clinical proteomics, and last per-
formed four kinds of validations: biological validation
(explainable index), exon array, statistical validation of
independent samples, and extensive pathway analysis.
Our results showed that alternative splicing isoform
makers can act as independent markers of breast cancer
and that the method we presented is an effective one for
increasing the number of identified alternative splicing
isoform markers in clinical proteomics.
Methods
Reagents
Ammonium carbonate, ammonium bicarbonate, urea,
formic acid, lysozyme, 2-Iodoethanol, and triethylpho-
sphine were all purchased from Sigma-Aldrich (St.
Louis, MO, USA). Acetonitrile and MS grade water were
purchased from Honey Burdick & Jackson (Morristown,
NJ, USA). Trypsin was purchased from Worthington
Biochemical Corporation (Lakewood, NJ, USA). Seppro
tip IgY-12 and reagent kit were purchased from GenWay
Biotech (San Diego, CA, USA).
Human plasma samples
Plasma protein profiles were collected by the Hoosier
Oncology Group (HOG) (Indianapolis, IN, USA) in two
batches, which we refer to as Study II and III (each con-
tained 40 plasma samples from women with breast can-
cer and 40 plasma samples from healthy age-matched
volunteer women as control). Most of patients involved
in the two studies were diagnosed with a stage II or III
or earlier breast cancer. Most patients had previously
been treated with chemotherapy. All samples were col-
lected with the same standard operating procedure and
stored in a central repository in Indianapolis, IN, USA.
The demography and clinical distribution of breast can-
cer stages/subtypes for Study II and III are comparable
(Additional file 1: Table S1). In Study II, there are 9 me-
tastasis and 30 non-metastasis, 30 INV and 10 DCIS,
mean tumor size 1.56, 8GI, 11 GII and 15 GIII. In Study
III, there are 1 metastasis and 20 non-metastasis, 23
INV and 8 DCIS, mean tumor size 1.93, 3GI, 9GII and
18GIII.
Proteomics methods
Biomarker identification and characterization holds great
promise for more precise diagnoses and for tailored
therapies. The heterogeneity of human cancers and un-
met medical needs in these diseases provides a compel-
ling argument to focus biomarker development in
cancer. Mass Spectrometry (MS)- based proteomics ap-
proaches have provided insight into biomarkers of can-
cer and other diseases with femtomole sensitivity and
high analytical precision. We presented a four steps
pipeline for the identification and validation of isoform-
specific peptide biomarkers from breast cancer proteo-
mics: Peptide Search Database Construction, Peptide
Identification and Quantification, Statistical Identifica-
tion of Isoform Markers, and Validation.
Peptide search database construction
A comprehensive database of human peptides character-
istic of all known and theoretic protein isoforms was de-
veloped in three steps: 1) obtaining gene structures of all
protein-coding genes in the human genome, 2) compil-
ing in silico isoform junction peptides, and 3) validating
those peptides in current protein knowledgebase.
First, we downloaded all information about human
genes in the Ensemble [13]. We retrieved gene informa-
tion such as name, position, exon phase, exon/intron co-
ordinates, and annotation. Exons which overlap with
each other were classified into a group, and a serial
number was assigned to each group according to its
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order in the sequence. For instance, the first group in
the gene would be marked as group one, and the second
as group two, etc. Introns can be obtained by the se-
quence between two exons.
Then, we generated in silico Isoform Junction Peptides
(IJP), which contains two types of peptides: the peptides
translated from all exons and the ones that are virtually
translated from all possible exon/intron junction regions.
Four types of exon/intron sequence joining types are
considered when generating IJPs: intron-exon (I_E_TH,
left intron retention junction), exon-intron (E_I_TH,
right intron retention junction), knowledgebase validated
exon-exon (E_E_KB, exon-exon junctions which can be
found in Ensembl transcripts) and theoretical exon-exon
(E_E_TH, exon-exon junctions which cannot be found
in Ensembl transcripts).
For those exons with the phase information in Ensem-
ble transcript, we directly used the phase to translate the
sequence. For those exons without the phase informa-
tion in Ensemble transcript, we designed an artificial
translation method as follows. This sequence is used to
generate three peptides, each of which has a different
opening reading frame (ORF) and a maximal length of
140 amino acid residues (longer than the longest pos-
sible peptide fragments directly obtained from a MS/MS
spectrum). The three ORFs are estimated in a validation
procedure, where the ORF will be discarded if a stop
codon is found in exon, knowledgebase validated exon-
exon, or theoretical intron-exon, or if a stop codon is
found in the first exon in theoretical exon-exon or the-
oretical exon-intron.
In the third and final step, we validated each IJP in the
ensemble transcript database. Those Ensemble predicted
transcripts have been mapped by Ensemble to full-
length or near-full-length protein sequence already avail-
able in the public sequence databases [13]. We labeled
the IJP as knowledge based (_KB) if it can be matched as
a substring of any ensemble transcript of the same en-
semble gene; otherwise, as theoretic (_TH).
Peptide identification and quantification
Proteins were prepared and subjected to LC/MS/MS
analysis. Samples were run on a Surveyor HPLC (Ther-
moFinnigan) with a C18 microbore column (Zorbax
300SBC18, 1 mm × 5 cm). All tryptic peptides (100 μL
or 20 μg) were injected onto the column in random
order. Peptides were eluted with a linear gradient from 5
to 45 % acetonitrile developed over 120 min at a flow
rate of 50 μL/min, and the eluant was introduced into a
ThermoFinnigan LTQ linear ion-trap mass spectrom-
eter. The data were collected in the “triple-play” mode
(MS scan, Zoom scan, and MS/MS scan).
We searched the OMSSA against the protein isoform
database we created to identify peptide. Peptide
quantification was carried out using the LC/MS-based
label-free protein quantification software licensed from Eli
Lilly and Company. Label-free peptide identification and
peptide quantitative analysis services were performed by
professionals at the Protein Analysis and Research Center/
Proteomics Core of Indiana University School of Medicine,
co-located at Monarch Life Sciences, Inc, Indianapolis. For
a thorough review of the principle and method developed
and used, refer to the review by Wang et al [14]. Briefly,
once the raw files were acquired from the LTQ, all ex-
tracted ion chromatograms (XIC) were aligned by retention
time. Each aligned peak should match parent ion, charge
state, daughter ions (MS/MS data) and retention time
(within a 1-min window). If any of these parameters were
not matched, the peak was disqualified from the quantifica-
tion analysis. After alignment, the area-under-the-curve
(AUC) from individually aligned peak was measured, nor-
malized, and compared for their relative abundance using
methods described in [15]. All peak intensities were trans-
formed to a log2 scale before quantile normalization. Pep-
tides with intensity lower than preset quality threshold are
marked as present; otherwise, as absent.
Statistical identification of isoform markers
Statistical Significance was measured by a three-step
method. First, we conducted a Chi-Square Goodness-of-
Fit Test to calculate the p value (also called false discov-
ery rate). Then we calculated the FDR adjusted p value.
Last, we calculated the FDR q value using the Storey-
Tibshirani method [16]. We chose a significance screen-
ing filters (q < 0.05) to select peptides of which we esti-
mated significant differences in the health and breast
cancer samples. The False Positive Rate (FPR) or ex-
pected proportion of false positive among the proteins
with declared changes is FPR = qvalue × number of the
proteins with declared changes.
Validation
Four validation methods including biological, statistical,
Exon Array and pathway validation methods were used
to validate our results. Biological validation was carried
out with Explainable Index. For gene, we define “Ex-
plainable Index” as
α ¼ conC þ 1
incC þ 1 ⋅
conH þ 1
incH þ 1 ;
where #con is the number of consistent peptide
markers and #inc is the number of inconsistent peptide
markers, C be cancer marker set and H be health marker
set. If α > 1, we define the gene to be “more explainable”;
and if α ≤ 1, we define the gene to be “less-explainable”.
The “consistent” is defined as one of following three
conditions:
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1) ∃i, j, k:Ej H&Ei_Ek C(i < j < k)
2) ∃j:Ej H and Ei_Ek(i < j < k)
3) ∃i, k:Ei_Ek C(i < k) and Ej(i < j < k);
And the “inconsistent” is defined as one of following
three conditions:
1) ∃i, j, k:Ej C&Ei_Ek H(i < j < k)
2) ∃j:Ej C and Ei_Ek(i < j < k)
3) ∃i, k:Ei_Ek H(i < k) and Ej(i < j < k).
For statistical validation, we used forward feedback
neural network to train Study II and then test Study
III. We chose each combination of N (N = 5 for five-
marker panel or N = 10 for ten-marker panel or N =
26 for twenty-six-marker panel) out of all the 26 dif-
ferentially expressed isoforms common in both Study
II (90) and B (79) as inputs to the FFNN. The train-
ing sets are 40 healthy and 40 cancer samples from
Study II. The testing sets are independent 40 healthy
and 40 cancer samples from Study III.
For a neural network, the output data has to be
transformed into binary or numerical data. A two-
variable outcome encoding scheme, i.e., healthy
= (0,1), cancer = (1,0) was used. In this scheme, it is
theoretically possible to have (1,1) or (0,0) as out-
comes although extremely rare. For the two variable
outcome encoding scheme, we constructed the input
layer as N nodes (corresponding to a N-marker panel
outcome), the hidden layer as 7 nodes, and the out-
put layer as 2 nodes.
In order to find the optimal classifier, we presented an
optimization method that measures the area under the
curve (AUC) for Receiver Operating Characteristics
(ROC). In this scheme, we first trained neural network
for each combination using Study II results. Then, we
measured the AUC for each combination using Study III
results for testing. Lastly, the optimal combination C*
was determined by
C ¼ argmin
c
AUC NETC ; Pð Þ;
where AUC is the area under the ROC curve of neural
network’s prediction result, NET is the trained neural
network, C is combination of picking N out of the 26
isoforms, and P is the testing set of Study III.
The Exon Array for validation was downloaded from
GSE19154 in Gene Expression Omnibus. R and BioCon-
ductor libraries were used to perform Exon Array analysis.
For pathway validation, the 90 alternative splicing bio-
markers in Study II and the 79 alternative splicing bio-
markers in Study III were used to perform pathway
analysis using the Kyoto Encyclopedia of Genes and Ge-
nomes (http://www.genome.ad.jp/kegg/) [17]. Significance
level for pathway comparisons was set by hit number >2
due to results of small counts. This allows avoiding any as-
sumptions about the shape of sampling distribution of
population.
Results
The statistics of IJP are shown in Table 1. Among the
5060822 peptides we derived, there are 208269 exon se-
quences, 222731 validated exon-exon junctions, 4109197
hypothetical exon-exon junctions, 413761 exon-intron
junctions and 106864 intron-exon junctions. There are
367956 normal exon-exon junctions, in which the com-
bined exons are continuous on the gene sequence, and
3963972 skipping exon-exon junctions. The longest exon
peptide length is 6057 amino acids (aa), and the average
exon length is 48 aa; the longest junction peptide length is
140 aa, and the average junction peptide length is 64 aa.
Alternative splicing peptides searching
In order to identify the tumor-specific alternative splicing
isoform patterns, we ran OMSSA search engine with the
peptide database against 40 normal plasma and 40 breast
cancer plasma in Study II. Maximum 1 missed cleavage,
Maximum 10 peptide hitlist length per spectrum, and
Evalue cutoff 1.0 were chosen for filtering peptides.
Statistics analysis
With the statistics analysis in the method section, 90 al-
ternative splicing isoforms in 38 genes were found,
which showed statistically significant (q < 0.05) differ-
ences between normal breast and breast cancer samples
in Study II (Additional file 2: Table S2; Fig. 1). Four out
of five kinds of alternative splicing isoforms: exon spli-
cing, single Exon, intron retention (left intron), and in-
tron retention (right intron) were identified (Fig. 2)
Table 1 The statistics of peptide database
Peptide
Type
Number of
Peptides
E_E Type Number of
Peptides
EXON_KB 208269 Normal E_E 367956
E_E_KB 222731 Skipping E_E 3963972
E_E_TH 4109197 Peptide Length
(aa)
E_I_TH 413761 Longest Exon 6057
I_E_TH 106864 Average Exon 48
Longest Junction 140
Total 5060822 Average Junction 64
Among the total 5060822 peptides, intron-exon junctions account for the
largest proportion, and theoretical exon-exon junctions the smallest
proportion. Majority of exon-exon junctions are normal, while the minority are
exon skipping. The average lengths are 64 and 48, for junction and exon,
respectively. The maximum of length are 140 and 6057, for junction and exon,
respectively. The peptide types are exon region (EXON_KB), annotated
exon-exon junctions (E_E_KB), hypothetical exon-exon junctions (E_E_TH),
hypothetical exon-intron junctions (E_I_TH), and hypothetical intron-exon
junctions (I_E_TH)
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except for the normal exon for which we fail to reject
the null hypothesis that there is no difference between
normal and cancer samples since the p-value is not less
than the significance level. Among the 90 alternative
splicing isoforms, 57 are exon splicing, 23 single Exon
and 10 intron retention. Those exon splicing and intron
retention markers are more likely to be present in cancer
samples than in normal samples and those single exon
markers are more likely to be present in normal samples
(χ2 = 53, df = 1, pvalue = 3.2e-13, Table 2). Another inter-
esting finding is that Alternative Splicing isoform
markers could be more likely to be found for genes with
two or more than two transcript variants encoding dif-
ferent isoforms than genes with only one transcript
(Chisquare Pvalue =1.35e-11 between genome and Study
II’s markers, Chisquare Pvalue =0 between genome and
Study III’s markers, Fig. 3). The human genome contains
totally 30370 genes with only one transcript and 19136
genes with two or more than two transcript variants.
Isoform Markers in Study II contains totally 3 genes
with only one transcript and 35 genes with two or more
than two transcript variants. Isoform Markers in Study
III contains totally 2 genes with only one transcript and
53 genes with two or more than two transcript variants.
Four validation methods
We presented four validation methods to validate our
results. First we used the explainable index defined in
method section to perform biological validation for the
38 gene markers. 36 out of 38 genes are “more explain-
able” except for two genes:JAK1 and KTN1 with explain-
able index of 1. The mean explainable index is 3.526316,
the median explainable index 2, and maximum 12.
We then performed the validation using the Human
Exon 1.0 ST Array we downloaded from GSE19154 in
Gene Expression Omnibus. The experiments include six
mRNA samples which were extracted from human
breast cancer cell line MCF7, and MCF10A, a nontu-
morigenic human breast epithelial cell line.
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Fig. 1 Heatmap of 90 alternative splicing isoform markers differentiating the normal and cancer samples of Study II. X axis is 90 alternative
splicing isoform markers. Y-axis shows the cancer and normal samples ordered by unsupervised clustering. The top are cancer samples and
bottom normal samples (H, health, green; C, cancer, blue). Red squares stand for presence, and white ones for absence
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Array analysis was performed using R and BioConduc-
tor libraries. Probeset in the exon array to the peptide
sequence in our database was performed using the
exon’s starting and ending positions in each transcript.
Because of the limitation of the exon array, we can only
validate the 23 single exon markers and test if those
markers are more likely to be expressed in the same
group as in our proteomics result. The validation results
show that 21 of 23 single exon markers were confirmed
by the exon array (Additional file 2: Table S2). The two
unconfirmed markers were identified with not very sig-
nificant pvalue (LLPNQNLPLDITLQSPTGAGPFPPIR
0.166; AAMKPGWEDLVRR 0.0895). The mutations that
alter a splice site or a nearby regulatory sequence may
have subtle effects by shifting the ratio of the resulting
proteins without entirely eliminating any form, as a re-
sult of alternate splicing.
Next, we performed the statistical validation using the
independent 40 healthy and 40 cancer samples from
Study III as testing set (Fig. 4). 66 (82.5 %) out of 80
samples are correctly predicted. For the 40 cancer sam-
ples, the prediction accuracy is 37/40 = 92.5 %.
Pathway analysis
Last, we performed extensive pathway analysis to dis-
cover highly significant pathways from a set of cancer vs
healthy samples. The knowledge of activation of these
processes may lead to novel assays identifying their
proteomic signatures in plasma of patient at high risk
for cancer disease. In Study II, of the 24 significant path-
ways we observed, at least 23 of these pathways were in-
volved cancers, signal transduction, diseases, and cellular
processes (Additional file 3: Table S3). The top pathways
include Pathways in cancer (8), MAPK signaling pathway
(3), Cell cycle (3), Apoptosis (3), Focal adhesion (3),
Adherens junction (3), Jak-STAT signaling pathway (3),
Prostate cancer (3). All are also significant pathways in
Study III except for Adherens junction (Additional file 4:
a) exon splicing
E8 E9 E10
TG(S)LDLLGDRSASSAGPQR C002
TG(S)LDLLGDRSASSAGPQR C007
TG(S)LDLLGDRSASSAGPQR C010
TG(S)LDLLGDRSASSAGPQR C026
TG(S)LDLLGDRSASSAGPQR C031
TG(S)LDLLGDRSASSAGPQR C032
TG(S)LDLLGDRSASSAGPQR C039
TG(S)LDLLGDRSASSAGPQR C049
MPL
b) single Exon
E22NCOA2
VNDPALRGGNLFPNQLPGMDMIK H553
VNDPALRGGNLFPNQLPGMDMIK H623
VNDPALRGGNLFPNQLPGMDMIK H628
VNDPALRGGNLFPNQLPGMDMIK H594
VNDPALRGGNLFPNQLPGMDMIK H748
c) normal exon
NOTCH2
YSCVCSPGFT(G)QRCNIDIDECASNPCR H647
E12 E13
d) intron retention (left intron)
i9
PPALPMSFA(E)EAVNEVKR C018
PPALPMSFA(E)EAVNEVKR C029
PPALPMSFA(E)EAVNEVKR C031
PPALPMSFA(E)EAVNEVKR C024
PPALPMSFA(E)EAVNEVKR C049
E10CBFA2T3
e) intron retention (right intron)
E5
YLNQFENCCGLREGAILTLLSDI(G)K C012
YLNQFENCCGLREGAILTLLSDI(G)K C027
YLNQFENCCGLREGAILTLLSDI(G)K C025
YLNQFENCCGLREGAILTLLSDI(G)K C051
i5IKBKB
Fig. 2 Five splicing types. Red, blue and green boxes are exon. Pink boxes are retained intron. Black lines are intron
Table 2 number of alternative splicing and normal markers
between the normal and cancer samples
Health cancer Total
Alternative Splicing 7 60 67
Normal 22 1 23
total 29 61
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Table S4). And ‘pathways in cancer’ are listed top 1 in
both Study II and Study III.
Discussion
In this study we developed a peptidomics approach to
identifying novel protein isoforms for clinical proteomics
application. First, we built a Peptidomic Database of Hu-
man Protein Isoforms, then created a peptidomics ap-
proach to perform large-scale screen of breast cancer-
associated alternative splicing isoform markers in clinical
proteomics, and last performed four kinds of validations:
biological validation (explainable index), exon array, stat-
istical validation of independent samples, and extensive
pathway analysis. Our results showed that alternative
splicing isoform makers can act as independent markers
of breast cancer and that the method we presented is an
effective one for increasing the number of identified al-
ternative splicing isoform markers in clinical proteomics.
The combination of protein isoform database, statis-
tical analysis, and statistical and biological validations
has the potential for extremely high-resolution signa-
tures to better resolve tumor subtypes and determining
optimal therapies.
Protein isoform database
With the advances in mass spectrometry (MS) and
large-scale generation of MS/MS (tandem MS)-based
proteomics data, it has become clear that MS-based
peptide sequence data can be mined to identify and val-
idate isoforms in the protein level rather than in the
transcript level where traditional methods such as EST
sequencing [4], exon array [6], Exon-exon junction array
[7]), and mRNA next-generation sequencing [8, 9] do.
Moreover, it can eliminate limitations with these trad-
itional methods for protein isoform determination such
as no connectivity about connection of nonadjacent
exons, no SNPs and PTMs, and low reproducibility.
However, there are some limitations in identifying pro-
tein isoforms using current MS proteomics search data-
base. For example, traditional mass spectrometry search
database using isoforms of well-known proteins is
biased. Using ESTs and a sequence database compres-
sion strategy to identify peptide isoforms existing in the
EST database from MS data [18] is also defective be-
cause of the inherent characteristics of ESTs, such as
transcript redundancy, low sequence quality and high
error rates. 282 novel open reading frames were identi-
fied by searching six-frame translation of the human
genome against MS spectrum [19]. But it only takes into
account a small portion of alternative splicing isoform.
Although there are several general-purpose alternative
splicing mRNA transcript databases including ASTD
[20], EID [21, 22], ASPicDB [23], and ECgene [24], they
cannot be used for searching uncharacterized protein
isoforms. And also the coverage of splicing junctions in
all the databases are small. The new PEPPI database [25]
contains the five types of combinations of exon and in-
tron: EXON_KB, E_E_KB, E_E_TH, E_I_TH and
I_E_TH, and makes it easy for different types of biomed-
ical users to search for and identify alternative splicing
isoform from proteomics experiment. We believe that it
will be useful in the ongoing analysis of proteomics data,
particularly those with clinical application potentials.
The current PEPPI database contains only alternative
splicing isoform. We will add SNP protein isoform and
PTM protein isoform in the future so that the database
of virtual peptides will be expanded to accommodate the
amino acid alterations introduced by each SNP and
PTM.
Biological significance of isoform-specific peptides
In this study, we have shown that isoform-specific pep-
tides can distinguish normal breast from breast cancer.
The number and type of splicing peptides identified ex-
ceeds the average number of events that is normally
identified by splicing microarray profiling [26]. The ac-
curacy and applicability of the newly identified alterna-
tive splicing signature was shown by its capacity to
identify breast cancer sample (Fig. 4). The signature
identified 92.5 % cancer samples and 72.5 % of normal
samples in an independent set of 40 normal samples and
40 breast cancer samples. All cancer samples that were
Fig. 3 Densities for genes with single transcript and multiple
transcripts across whole genome, Study II’s markers and Study III’s
markers. It shows that alternative splicing isoform markers could be
more likely to be found for genes with two or more than two
transcript variants encoding different isoforms than genes with only
one transcript (Chisquare Pvalue =1.35e-11 between genome and
Study II’s markers, Chisquare Pvalue =0 between genome and Study
III’s markers)
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identified as normal could be either of the complexity of
the proteome in plasma samples where the low abun-
dance expected for specific markers of cancer are hin-
dered, or of false positive associations that occur with
analysis of high dimensional database.
We observed that there appeared to be a higher pro-
portion of alternative splicing markers in cancer samples
(58 out of 65 alternative splicing are predominant in the
cancer samples) and a higher proportion of normal
markers in normal samples (22 out of 23 normal splicing
Fig. 4 Heatmap of 26 alternative splicing isoform markers in Study II differentiating the normal and cancer samples of Study III. X axis is 26
alternative splicing isoform markers from Study II. Y-axis shows the cancer and normal samples in Study III ordered by unsupervised clustering.
The top are health samples and bottom cancer samples. The prediction results are green for health and blue for cancer. Red squares stand for
presence, and white ones for absence
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are predominant in normal samples). Those exon spli-
cing and intron retention markers are more likely to be
present in cancer samples than in normal samples and
those single exon markers are more likely to be present
in normal samples. The strong correlation of alternative
splicing isoform with cancer suggests the potential value
of alternative splicing as prospective markers for the
early detection and treatment of cancer.
Interestingly, we also found that alternative splicing
isoform markers could be more likely to be found for
genes with two or more than two transcript variants en-
coding different isoforms than genes with only one tran-
script (Fig. 3).
Previously, many alternative splicing variants had been
observed in cancer, for examples, EGFR, CD44, NER
and BRCA1. In our 38 gene markers, alternative splicing
events of at least 5 genes were previously reported to
occur in cancer.
Two single exon markers and nine alternative splicing
markers for ATM were identified in our results. This
gene and the closely related kinase ATR are master con-
trollers of cell cycle checkpoint signaling pathways that
are required for cell response to DNA damage and for
genome stability. Three alterations, del exon 4, deletion
exon 29–34 and insertion of 137 bp in exon 46/47 were
commonly observed in 8 HL cell lines and 7 clinical
cases [27]. Katzenberger etc. presented the evidence that
the ATM/CHK2 and ATR/CHK1 signaling pathways
control gene expression by regulating alternative splicing
[28]. Ho et. al. used ATM sequence alterations located
within exons or in short intron regions flanking each
exon that encompass putative splice site regions as pre-
dictor for late normal tissue responses in breast cancer
patients treated with radiotherapy [29]. ATM allelic vari-
ants were reported to be associated to hereditary breast
cancer in 94 Chilean women [30]. ATM SNPs have been
associated with increased risk of breast, prostate, leukae-
mia, colon and lung cancer. Nguyen etc used two exons
of ATM, both containing an SNP interfering with stand-
ard mutation scanning to screen 1356 subjects from an
international breast cancer genetics Study IInd improved
identification of rare known and unknown variants,
while dramatically reducing the sequencing effort [31].
Three splicing markers (E3_E10 exon splicing, i6 in-
tron retention and E5 single exon) for MET were identi-
fied in our results. The first two were predominant in
cancer samples and the last one was predominant in
health samples. Lee etc. had detected a novel type of
structural variant of the tyrosine kinase receptor for
MET, also known as the hepatocyte growth factor recep-
tor, in mouse tissues, and demonstrated that a tyrosine
kinase receptor could achieve additional diversity by al-
ternative splicing at a key regulatory site in its cytoplas-
mic domain [32]. The cDNA of the variant transcript of
MET lacks 141 base pairs and causes an in-frame deletion
of 47 amino acids in the juxtamembrane region of the cyto-
plasmic domain. Extensive evidences indicate that MET sig-
naling is involved in the progression and spread of several
cancers such as breast, liver, lung, ovary, kidney, and thy-
roid [33]. And understanding of its role in disease has led
to the development of Met as a major target in cancer drug
and the development of a variety of MET pathway antago-
nists with potential clinical applications. Various mutations
in the MET gene were reported to be associated with can-
cers. Zohar Tiran etc. identified a novel splice variant of the
Met receptor, which encodes a truncated soluble form of
the receptor [34]. This variant was produced as a recom-
binant Fc-fused protein named Cgen-241A and significantly
inhibited HGF/SF-induced MET phosphorylation as well as
cell proliferation, survival, and a profound inhibitory effect
on cell scattering, invasion, and urokinase up-regulation.
CREBBP is ubiquitously expressed and is involved in
the transcriptional coactivation of many different tran-
scription factors. First isolated as a nuclear protein that
binds to cAMP-response element binding protein
(CREB), this gene is now known to play critical roles in
embryonic development, growth control, and homeosta-
sis by coupling chromatin remodeling to transcription
factor recognition. Its alternative splicing results in mul-
tiple transcript variants encoding different isoforms. It
was reported that Co-regulator expression of CREBBP/
p300 had been associated with lower tumor grade [35].
We identified intron 14 of JAK1 was retained through
translation, which might be related to the mutation of
14 exons of JAK1 [36]. Xie found 12 cases (14 %) found
to have single nucleotide polymorphism in exon 14.
Somatic mutations in the SMO gene have also been
identified in breast cancer. Recently, two groups have
shown that hedgehog signaling may be active in a subset
of human breast cancer cell lines, and that SMO antago-
nists can inhibit breast cancer growth [37, 38].
Conclusions
We developed a peptidomics method to discover novel
alternative splicing biomarkers from breast cancer prote-
ome. First, we built a Peptidomic Database of Human
Protein Isoforms, then created a peptidomics approach
to perform large-scale screen of breast cancer-associated
alternative splicing isoform markers in clinical proteo-
mics, and last performed four kinds of validations: bio-
logical validation (explainable index), exon array,
statistical validation of independent samples, and exten-
sive pathway analysis. Our results showed that alterna-
tive splicing isoform makers can act as independent
markers of breast cancer and that the method we
presented is an effective one for increasing the number
of identified alternative splicing isoform markers in clin-
ical proteomics.
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